Medtronic plans to spin off diabetes business - report

Published 21/05/2025, 10:28
© Reuters.

Investing.com -- Medtronic (NYSE:MDT), the medical-device maker, is planning to separate its diabetes division into an independent, publicly traded company, the Wall Street Journal reported on Wednesday.

The diabetes division of Medtronic generated close to $2.5 billion in sales for the fiscal year that ended in April 2024, marking a 10% increase from the previous year.

Overall, Medtronic reported more than $32 billion in sales for the same year.

The separation process, which is expected to be completed within 18 months, will allow the diabetes business to grow at a faster rate, the Journal reported.

It will also enable Medtronic, which is based in Galway, Ireland but operates out of Minneapolis, to boost the growth of its other divisions, it added.

The new company, yet to be named, will be publicly traded, the report said.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.